Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Allogene Therapeutics, Inc. (ALLO) had Free Cash Flow per Share of $-0.05 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-42.61M |
|
-- |
|
-- |
|
$46.09M |
|
$-46.09M |
|
$3.48M |
|
$-42.61M |
|
$-42.61M |
|
$-42.61M |
|
$-42.61M |
|
$-42.61M |
|
$-42.61M |
|
$-46.09M |
|
$-44.11M |
|
240.29M |
|
240.29M |
|
$-0.18 |
|
$-0.18 |
|
| Balance Sheet Financials | |
$273.29M |
|
$70.02M |
|
$122.67M |
|
$395.96M |
|
$28.33M |
|
-- |
|
$88.75M |
|
$117.08M |
|
$278.88M |
|
$278.88M |
|
$278.88M |
|
244.82M |
|
| Cash Flow Statement Financials | |
$-12.91M |
|
$-29.59M |
|
$21.12M |
|
$61.98M |
|
$40.60M |
|
$-21.38M |
|
$8.27M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.65 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.92M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.28% |
|
-15.28% |
|
-10.76% |
|
-15.28% |
|
$1.14 |
|
|
Free Cash Flow per Share |
$-0.05 |
$-0.05 |
|